Dupixent Shows Promise in Treating Atopic Dermatitis in Patients with Skin of Color

Atopic dermatitis (AD), commonly known as eczema, presents a significant challenge for individuals with skin of colour due to its often more severe nature and pronounced symptoms. However, recent advancements in treatment options have brought hope for effective management.

Dupilumab Shows Promise

A Phase IV clinical trial, known as DISCOVER, conducted by Regeneron Pharmaceuticals and Sanofi, has unveiled promising results regarding the efficacy of Dupixent (dupilumab) in treating moderate-to-severe AD in adolescents and adults with skin of colour. The findings were presented at the 2025 Revolutionizing Atopic Dermatitis Conference.

In the DISCOVER trial, 120 participants with AD and skin of colour received Dupixent biweekly for a period of 24 weeks. At the conclusion of the study, a remarkable 76% of the subjects achieved a ≥75% improvement in their overall disease severity. Notably, some patients reported experiencing benefits as early as two weeks after initiating treatment.

Reduced Itching and Improved Skin Appearance

Furthermore, the trial demonstrated a significant reduction in itching for 53% of the patients, along with a 53% decrease in post-inflammatory hyperpigmentation from their baseline levels. These results highlight Dupixent's potential to not only alleviate symptoms but also improve the overall appearance of the skin.

Safety outcomes from the DISCOVER trial were consistent with Dupixent’s established safety profile in dermatological applications. Subjects aged 12 years and above received Dupixent monotherapy based on their weight. The primary endpoint was achieving a minimum 75% improvement on the Eczema Area and Severity Index (EASI-75) at 24 weeks, with secondary endpoints focusing on itch reduction and improvements in skin lesions.

Dupixent is a monoclonal antibody that effectively blocks the signalling of interleukin-4 and interleukin-13 pathways without compromising the immune system. Developed using Regeneron's VelocImmune technology, it represents a collaborative effort between Sanofi and Regeneron. The successful results of the DISCOVER trial provide compelling evidence that Dupilumab shows promise in offering a new and effective treatment option for individuals with moderate-to-severe AD and skin of colour.

The establishment of safety through clinical trials is crucial for gaining widespread acceptance and trust in any new medication. In this regard, the DISCOVER trial further reinforces the safety profile of Dupixent, enabling healthcare professionals to confidently prescribe it to their patients.